Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDEXX LaboratoriesFRA:IX1 +0.47%96 Return-on-Tangible-Asset is 39.36% as of Mar. 2026, which is 24% above its 10-year median of 31.82. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €577.54 (Modestly Undervalued). Among 213 Medical Diagnostics & Research companies, IDEXX Laboratories ranks better than 97.18% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. IDEXX Laboratories's annualizedNet Income for the quarter that ended in Mar. 2026 was €963 Mil. IDEXX Laboratories's average total tangible assets for the quarter that ended in Mar. 2026 was €2,448 Mil. Therefore, IDEXX Laboratories's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 39.36%.
The historical rank and industry rank for IDEXX Laboratories's Return-on-Tangible-Asset or its related term are showing as below:
FRA:IX1'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 17.44 Med: 31.82 Max: 38.93
Current: 38.93
During the past 13 years, IDEXX Laboratories's highest Return-on-Tangible-Asset was 38.93%. The lowest was 17.44%. And the median was 31.82%.
FRA:IX1's Return-on-Tangible-Asset is ranked better than 97.18% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs FRA:IX1: 38.93
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
IDEXX Laboratories Return-on-Tangible-Asset Related Terms
IDEXX Laboratories Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IX1 vs A, NTRA, WAT: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, IDEXX Laboratories's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 39.36% mean?
IDEXX Laboratories (FRA:IX1) has a Return-on-Tangible-Asset of 39.36% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on IDEXX Laboratories and its competitors. This is 24% above median its historical median of 31.82. Over the past decade, IDEXX Laboratories' Return-on-Tangible-Asset has ranged from 17.44 to 38.93. According to the industry distribution chart, IDEXX Laboratories ranks #6 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 2.8%.
Is IDEXX Laboratories' Return-on-Tangible-Asset too high?
IDEXX Laboratories' current Return-on-Tangible-Asset of 39.36% is 24% above median its 10-year median of 31.82. Over the past 10 years, this metric has ranged from a low of 17.44 to a high of 38.93. Based on the distribution chart, IDEXX Laboratories ranks #6 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Return-on-Tangible-Asset compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #6 out of 213 companies for Return-on-Tangible-Asset. This places IDEXX Laboratories in the top 3% of its industry — outperforming the majority of peers. Historically, IDEXX Laboratories' own Return-on-Tangible-Asset has ranged from 17.44 to 38.93 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current Return-on-Tangible-Asset is 39.36%, which is 24% above median its own 10-year median of 31.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €577.54, compared to a current price of €492.80 — trading 14.7% below its estimated fair value. The current Return-on-Tangible-Asset is 39.36%, which is 24% above median its 10-year median of 31.82. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Return-on-Tangible-Asset is 39.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €492.80 is trading 14.7% below its estimated GF Value™ of €577.54.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
Return-on-Tangible-Asset: 39.36% (24% above median its 10-year median of 31.82)
GF Value™: €577.54 vs. price of €492.80 (14.7% below fair value)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
